Rheumatology International

, Volume 27, Issue 7, pp 649–654 | Cite as

Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: preliminary results

  • Paola Caramaschi
  • Orazio Ruzzenente
  • Sara Pieropan
  • Alessandro Volpe
  • Antonio Carletto
  • Lisa Maria Bambara
  • Domenico Biasi
Original Article

Abstract

To evaluate ANA specificity using the fully automated multiplexed fluorescent microsphere immunoassay in patients affected either by rheumatoid arthritis or ankylosing spondylitis who developed strong positivity for ANA as assessed by indirect immunofluorescent method on HEp-2 cells during infliximab treatment. Three men affected by ankylosing spondylitis and 12 women affected by rheumatoid arthritis who developed ANA positivity at high titres during infliximab treatment underwent the identification of ANA specificity by multiplexed fluorescent microsphere immunoassay; moreover anti-DNA and anti-ENA antibodies were tested by indirect immunofluorescence and ELISA method, respectively. In 4 out of 15 cases, the determination of ANA reactivity by multiplexed fluorescent microsphere immunoassay was also performed on the serum collected before infliximab administration. One patient affected by rheumatoid arthritis showed multiple ANA reactivities against SS-A, SS-B, RNP, Sm, Jo-1 and histones; one patient affected by ankylosing spondylitis resulted positive for the same autoantibodies, except for anti-Sm antibody. Moreover, two patients, one with rheumatoid arthritis and one with ankylosing spondylitis, showed single antibody specificity to SS-B and RNP, respectively. The remaining 11 cases did not show any positivity. Instead, all the patients resulted negative for anti-ENA antibodies by the ELISA method. In the four cases tested for ANA specificity by multiplexed fluorescent microsphere immunoassay before and after infliximab administration no difference was found. The search for anti-DNA antibody always resulted negative by both the traditional immunofluorescent assay and the novel technique. The use of multiplexed fluorescent microsphere immunoassay in patients treated with infliximab with ANA positivity at high titres allowed to find some ANA specificities which were not revealed by ELISA method. Nevertheless, the majority of patients resulted negative in spite of ANA positivity at high titres; the molecular target of ANA which develop after infliximab administration still remains to be identified.

Keywords

Antinuclear antibodies Multiplexed fluorescent microsphere immunoassay Infliximab Rheumatoid arthritis Ankylosing spondylitis 

References

  1. 1.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys E, De Keyser F (2005) Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity. Biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 52:2192–2201PubMedCrossRefGoogle Scholar
  2. 2.
    Forger F, Matthias T, Oppermann M, Becker H, Helmke K (2004) Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus 13:36–44PubMedCrossRefGoogle Scholar
  3. 3.
    Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N (2004) Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 6:R535–R543PubMedCrossRefGoogle Scholar
  4. 4.
    Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A, Volpe A, Pacor ML, Bambara LM (2006) Anti-TNF α therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int 26:209–214PubMedCrossRefGoogle Scholar
  5. 5.
    Atzeni F, Sarzi-Puttini P, Dell’Acqua D, de Portu S, Cecchini G, Cruini C, Carrabba M, Meroni PL (2005) Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 8:R3CrossRefGoogle Scholar
  6. 6.
    De Bandt M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C, Boucquillard E, Siame JL, Mariette X, Club Rhumatismes et Inflammation (2005) Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7:R545–R551Google Scholar
  7. 7.
    Charles PJ, Smeenk RJT, De Jong J, Feldmann M, Maini RN (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α. Arthritis Rheum 43:2383–2390PubMedCrossRefGoogle Scholar
  8. 8.
    Bickerstaff MC, Botto M, Hutchinson WL, Herbert J, Tennent GA, Bybe A, Mitchell DA, Cook HT, Butler PJ, Walport MJ, Pepys MB (1999) Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 5:694–697PubMedCrossRefGoogle Scholar
  9. 9.
    Gershow D, Kim S, Brot N, Elkon KB (2000) C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 192:1353–1364CrossRefGoogle Scholar
  10. 10.
    Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD (2001) In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 167:6821–6826PubMedGoogle Scholar
  11. 11.
    Von Muhlen CA, Tan EM (1995) Antibodies in diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 24:232–258Google Scholar
  12. 12.
    Martins TB, Burlingame R, von Muhlen CA, Jaskowski TD, Litwin CM, Hill HR (2004) Evaluation of multiplexed fluorescent microsphere immunoassay for detection of autoantibodies to nuclear antigens. Clin Diagn Lab Immunol 11:1054–1059PubMedCrossRefGoogle Scholar
  13. 13.
    Pang S, Smith J, Onley D, Reeve J, Walker M, Foy CA (2005) Comparability study of the emerging protein array platforms with established ELISA procedures. J Immunol Methods 302:1–12PubMedCrossRefGoogle Scholar
  14. 14.
    Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, Jones JA, Harley JB (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526–1533PubMedCrossRefGoogle Scholar
  15. 15.
    Favalli EG, Sinigaglia L, Varenna M, Arnoldi C (2000) Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 11:753–755CrossRefGoogle Scholar
  16. 16.
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552–1563PubMedCrossRefGoogle Scholar
  17. 17.
    Maini RN, St Clair EW, Breedveld FC, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 354:1932–1939PubMedCrossRefGoogle Scholar
  18. 18.
    De Bandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O (2003) Anti-TNF-alpha-induced systemic lupus erythematosus. Clin Rheumatol 22:56–61CrossRefGoogle Scholar
  19. 19.
    Klapman JB, Ene-Stroescu D, Becker MA, Hananuer SB (2003) A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 9:176–178PubMedCrossRefGoogle Scholar
  20. 20.
    Mohan AK Edwards ET, Coté TR, Siegel JN, Braun MM (2002) Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 360:646CrossRefGoogle Scholar
  21. 21.
    Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P (2002) Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn’s disease: a prospective cohort study. Gastroenterology 125:32–39CrossRefGoogle Scholar
  22. 22.
    Sarzi-Puttini P, Ardizzone S, Manzionna G, Atzeni F, Colombo E, Antivalle M, Carrabba M, Bianchi-Porro G (2002) Infliximab-induced lupus in Crohn’s disease: a case report. Dig Liver Dis 35:814–817CrossRefGoogle Scholar
  23. 23.
    Hanauer SB (1999) Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 13(suppl 4):16–22PubMedCrossRefGoogle Scholar
  24. 24.
    Shovman O, Gilburd B, Zandman-Goddard G, Yehiely A, Langevitz P, Shoenfeld Y (2005) Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases. Autoimmunity 38:105–109PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Paola Caramaschi
    • 1
    • 3
  • Orazio Ruzzenente
    • 2
  • Sara Pieropan
    • 1
  • Alessandro Volpe
    • 1
  • Antonio Carletto
    • 1
  • Lisa Maria Bambara
    • 1
  • Domenico Biasi
    • 1
  1. 1.Dipartimento di Medicina Clinica e SperimentaleUniversità di VeronaVeronaItaly
  2. 2.Dipartimento di Scienze Morfologico-BiomedicheUniversità di VeronaVeronaItaly
  3. 3.Istituto Medicina Interna BPoliclinico G.B. RossiVeronaItaly

Personalised recommendations